The US Centres for Disease Control and Prevention (CDC) and Food and Drug Administration (FDA) have announced a plan to offer ...

The FDA issued draft guidance on oncology clinical trials, taking the first steps toward formalizing a position that it's ...

Pharma giant Pfizer said that a drug aimed at helping cancer patients losing appetite and muscle mass showed positive results ...

In the United States and some countries other than Europe, Lilly owns exclusive development and commercialization rights to ...

Ponsegromab reached a clinically meaningful 5.6% mean weight increase at the high dose level in patients with cancer cachexia ...

The company reported Health Canada authorized the use of its Spikevax KP.2 shot for those aged six months and older. Last ...

Respiratory syncytial virus (RSV) vaccination in adults aged 60 years and older may be cost-effective in preventing illness, ...

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any breaking news developments ...

AstraZeneca is continuing to study AZD8205 as a monotherapy in dose optimization expansion cohorts of patients with ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced its Phase 2 study ... iv Despite its severity, there are no FDA-approved treatments for cachexia. iii About Ponsegromab Ponsegromab ...

Pfizer Inc. (PFE) announced longer-term follow-up results from the Phase 2 single-arm PHAROS clinical trial evaluating the efficacy ...

Pfizer Inc. (NYSE: PFE) experienced a notable uptick in its stock price during Monday’s trading session, climbing by +2.12% to reach $29.89 at 11:10 AM EDT. This positive movement comes in the wake of ...